|
T2701 |
GSK1292263
|
|
GPR
|
|
GSK1292263 is a GPR119 agonist and has been investigated for the treatment of DIABETES MELLITUS, TYPE 2. |
|
T9022 |
AZD9977
|
AZD 9977 |
Glucocorticoid Receptor
|
|
AZD9977 is a novel, selective modulator of mineralocorticoid receptor . |
|
T15432 |
GSK256073
|
|
GPR
,
Others
|
|
GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist (pEC50: 7.5). GSK256073 acutely improves glucose homeostasis via inh... |
|
T12710 |
Retagliptin Phosphate
|
SP 2086 |
Proteasome
,
DPP-4
|
|
Retagliptin Phosphate (SP 2086) is pharmaceutical composition of DPP-4 inhibitor, for treating type-2 diabetes. |
|
T2371 |
Emapunil
|
AC-5216,XBD-173 |
Others
|
|
Emapunil (XBD-173) is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. |
|
T8780 |
AMG131
|
INT-131,AMG-131,CHS 131 |
PPAR
|
|
AMG131 (CHS 131) , is a novel, non-thiazolidinedione (TZD), selective peroxisome proliferator-activated receptor (PPAR)gamma modulator, which can be used for the treatment of type 2 diabetes mellitus (non-insulin depende... |
|
TP1796 |
Albiglutide TFA (782500-75-8 free base)
|
Albiglutide TFA |
Glucagon Receptor
|
|
Albiglutide TFA (782500-75-8 free base) (Albiglutide TFA) is a long acting GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus (T2DM). |
|
T27439 |
GS-9667
|
CVT-3619,CVT 3619 |
Adenosine Receptor
|
|
GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). |
|
T77781 |
Lotiglipron
|
PF-07081532 |
Glucagon Receptor
|
|
Lotiglipron (PF-07081532) is an orally active and potent GLP-1R agonist that reduces blood glucose and body weight and may be useful in the study of type 2 diabetes mellitus (T2DM) and obesity. |
|
TP1469 |
Lixisenatide acetate (320367-13-3 free base)
|
Lixisenatide acetate |
Glucagon Receptor
|
|
Lixisenatide acetate is a receptor agonist similar to glucagon-like peptide-1 (glp-1) for the treatment of type 2 diabetes mellitus (T2DM). |
|
T27841 |
Lobeglitazone Sulfate
|
CKD501 Sulfate,CKD501,CKD-501 Sulfate,CKD 501 Sulfate,CKD 501,CKD-501,Lobeglitazone Sulfate. trade name Duvie, Chong Kun Dang |
NOD
|
|
Lobeglitazone Sulfate（CKD-501 Sulfate） is a novel thiazolidinedione with anti-inflammatory activity that inhibits LPS-induced NLRP3 inflammasome activation and hepatic inflammation, and can be used in the study of type 2... |
|
T67898 |
α-Glucosidase-IN-22
|
|
Glucosidase
|
|
α-Glucosidase-IN-22 is a selective inhibitor of α-glucosidase (IC50=0.64 μM). α-Glucosidase-IN-22 has antidiabetic activity and has potential in type 2 diabetes (T2DM) studies. |
|
T16486 |
Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD
|
PF-05231023 |
FGFR
,
PROTAC Linker
|
|
Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (PF-05231023) is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM. |
|
T6237 |
Trelagliptin
|
SYR-472 |
Proteasome
,
DPP-4
|
|
Trelagliptin (SYR-472) is a highly specific and long-acting DPP-4 inhibitor. |
|
T4460 |
Dapagliflozin ((2S)-1,2-propanediol, hydrate)
|
BMS-512148 (2S)-1,2-propanediol, hydrate,Dapagliflozin propanediol monohydrate |
SGLT
|
|
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in development for the tre... |
|
T2296 |
Trelagliptin succinate
|
SYR-472 succinate,SYR472 |
Proteasome
,
DPP-4
|
|
Trelagliptin succinate (SYR-472 succinate) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D). |
|
T15810 |
LY2922470
|
|
GPR
|
|
LY2922470 reduces glucose levels along with significant enhancements in insulin and GLP-1, which is the potential for the treatment of type 2 diabetes mellitus (T2DM). LY2922470 is an effective, selective, and orally ava... |
|
T11416 |
Glucagon receptor antagonists-5
|
|
Others
|
|
Glucagon receptor antagonists-5 is an orally bioavailable indazole-based glucagon receptor antagonist (Ki: 32 nM). It has potential for the treatment of type 2 diabetes mellitus (T2DM). |
|
T78313 |
Fazpilodemab
|
BFKB8488A |
FGFR
|
|
Fazpilodemab (BFKB8488A) is a humanized agonistic bispecific antibody that targets fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. It is utilized in research pertaining to Type 2 diabetes mellitus (T2DM) and n... |
|
T38539 |
Luseogliflozin hydrate
|
TS 071 hydrate |
|
|
Luseogliflozin (TS 071) hydrate, a second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibits selective potency and oral activity, with an IC50 of 2.26 nM. This compound is utilized in research for the... |
|
T13022L |
SSTR5 antagonist 2 TFA
|
|
Others
|
|
SSTR5 antagonist 2 TFA is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5), with potential to treat type 2 diabetes mellitus (T2DM). |
|
T13022 |
SSTR5 antagonist 2
|
|
Others
|
|
SSTR5 antagonist 2 is a highly potent, oral active and selective antagonist of somatostatin (receptor) subtype 5 (SSTR5),with potential to treat type 2 diabetes mellitus (T2DM). |
|
TP1340 |
Lixisenatide
|
|
|
|
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).It is an injectable diabetes medicine that helps control blood sugar levels. |
|
T40349 |
DS45500853
|
|
|
|
DS45500853, an estrogen-related receptor α (ERRα) agonist, acts as an inhibitor of the binding interaction between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain ... |
|
T78731 |
α-Glucosidase-IN-26
|
|
Glucosidase
|
|
α-Glucosidase-IN-26 (Compound 7i), with an IC50 value of 4.63 µM, functions as an α-glucosidase inhibitor and is utilized in research related to type 2 diabetes mellitus (T2DM) [1]. |
|
T62985 |
Cofrogliptin
|
|
|
|
Cofrogliptin (HSK7653) (compound 2) is a tetrahydropyran derivative that is an orally active DPP-4 inhibitor with long-lasting hypoglycaemic effects.Cofrogliptin (compound 2) has potential for studies in type 2 diabetes ... |
|
T78703 |
PTP1B/AKR1B1-IN-2
|
|
Phosphatase
|
|
PTP1B/AKR1B1-IN-2 (Compound 7f) is a potent inhibitor targeting both PTP1B and AKR1B1 with IC50 values of 3.2 and 2.1 μM, respectively, and K i values of 4.0 and 0.9 μM. This compound acts as an insulin mimetic and enhan... |
|
T60203 |
INCB13739
|
|
|
|
INCB13739 is an orally active, potent, selective, and tissue-specific inhibitor of 11β-HSD1 (11β-hydroxysteroid dehydrogenase 1), demonstrating IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC). It is... |
|
T78881 |
α-Glucosidase-IN-36
|
|
Glucosidase
|
|
α-Glucosidase-IN-36 (compound 5g) is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 6.69 ± 0.18 μM and inhibition constants Ki and Kis of 1.65 μM and 4.54 μM, respectively. It is hypothesized to suppres... |
|
T70391 |
AMG151 HCl
|
|
|
|
ARRY-403, also known as AMG-151, is an orally available allosteric glucokinase (GK) activator developed for the treatment of type 2 diabetes mellitus (T2DM). ARRY-403 has many favorable physicochemical characteristics an... |
|
T79358 |
PF-07247685
|
|
Endogenous Metabolite
|
|
PF-07247685, a potent BCKDC kinase (BDK) inhibitor (EC 50 = 2.2 nM), enhances the binding between BDK and the BCKDH E2 core subunit to block E1 phosphorylation. BDK regulation is crucial for BCKDH activity, which manages... |
|
T60759 |
DS20362725
|
|
|
|
DS20362725 is an agonist of estrogen-related receptor α (ERRα) that is able to be used for the metabolic disorders research, for example, type 2 diabetes mellitus (T2DM). The IC 50 value of DS20362725 inhibiting the bind... |
|
T78702 |
PTP1B/AKR1B1-IN-1
|
|
Phosphatase
|
|
PTP1B/AKR1B1-IN-1 is a dual inhibitor targeting protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), exhibiting inhibitory potency with IC50s of 0.06 μM for PTP1B and 4.3 μM for AKR1B1. Additionally, it... |
|
T79357 |
PF-07238025
|
|
Endogenous Metabolite
|
|
PF-07238025, a potent branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with an EC50 of 19 nM, enhances the stability of the BDK-BCKDH core E2 subunit interaction and inhibits the phosphorylation of the E1 sub... |
|
TMIH-0583 |
Trelagliptin-13C-d3
|
|
|
|
Trelagliptin-13C-d3 is the 13C and deuterated compound of Trelagliptin. Trelagliptin has a CAS number of 865759-25-7. Trelagliptin is a highly specific and long-acting DPP-4 inhibitor. |
